Literature DB >> 3828220

A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis.

R Cerio, G M Murphy, G E Sladen, D M MacDonald.   

Abstract

A patient with primary biliary cirrhosis is reported in whom UV phototherapy alone was repeatedly effective in controlling severe pruritus. Symptomatic relief was sustained by introducing cholestyramine at a low dosage, despite previous failure of the drug alone to produce any therapeutic benefit, even in large doses. Bile acid concentrations were measured in sera, urine and suction blister fluid from skin exposed to ultraviolet light before, during and following treatment. The findings suggest that phototherapy reduces cutaneous bile acid levels which can subsequently be maintained by low dose cholestyramine. Routine liver function tests remained unaltered. This combination of phototherapy and cholestyramine may be useful in controlling severe pruritus in primary biliary cirrhosis when the drug alone is not tolerated or is ineffective.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3828220     DOI: 10.1111/j.1365-2133.1987.tb05825.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.

Authors:  G V Gregorio; C S Ball; A P Mowat; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

2.  Lichen planus associated with chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution.

Authors:  J P Ellul; R Groves; J R Walters; G M Murphy
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

3.  Refractory pruritus in primary biliary cirrhosis.

Authors:  Nuno Cercas Pinheiro; Rui Tato Marinho; Fernando Ramalho; José Velosa
Journal:  BMJ Case Rep       Date:  2013-11-14

Review 4.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.